A-425619

Synonyms: 化合物A 425619
A-425619 是一种具有口服活性和选择性的瞬时受体电位 V1 型 (TRPV1) 拮抗剂,可阻断 Capsaicin (MS-R45786) 和 N-花生四烯酰多巴胺 (NADA) 诱导的背根神经节和三叉神经节中的 Ca2+ 流入,缓解大鼠中与炎症和组织损伤相关的病理性疼痛,并可用于研究与炎症和组织损伤相关的疼痛。
产品编号: MS-R05415 纯度: 99.96% CAS No.: 581809-67-8 分子式: C18H14F3N3O 分子量: 345.32
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

A-425619 是一种具有口服活性和选择性的瞬时受体电位 V1 型 (TRPV1) 拮抗剂,可阻断 Capsaicin (MS-R45786) 和 N-花生四烯酰多巴胺 (NADA) 诱导的背根神经节和三叉神经节中的 Ca2+ 流入,缓解大鼠中与炎症和组织损伤相关的病理性疼痛,并可用于研究与炎症和组织损伤相关的疼痛。

生物实验数据

生物活性 A-425619 is an orally active and selective transient receptor potential vanilloid 1 (TRPV1) antagonist that blocks Capsaicin (MS-R45786)- and N-arachidonoyl dopamine (NADA)-induced Ca2+ influx in dorsal root ganglia and trigeminal ganglia, alleviates pathological pain associated with inflammation and tissue injury in rats, and can be used for research on pain associated with inflammation and tissue injury.
IC50 & Target TRPV1:3-9 nM
体外研究
(In Vitro)

A-425619 (10 μM) 阻断 500 nM Capsaicin (MS-R45786) 诱导的背根神经节 (IC50 = 78 nM) 和三叉神经节 (IC50 = 115 nM) 中的 Ca2+ 流入,并抑制 3 μM N-花生四烯酰多巴胺 (NADA) 诱导的背根神经节 (IC50 = 36 nM) 和三叉神经节 (IC50 = 37 nM) 中的 Ca2+ 流入。
A-425619 (100 nM) 可完全抑制背根神经节和三叉神经节神经元中 TRPV1 介导的酸激活电流。
A-425619 (0.01-1 μM) 可显著阻断 300 nM Capsaicin 和 3 μM NADA 诱导的背根神经节中降钙素基因相关肽 (CGRP) 释放。
A-425619 (3-100 nM) 强效阻断大鼠背根神经节神经元中天然 TRPV1 通道的激活 (IC50 = 9 nM)。

体内研究
(In Vivo)

A-425619 (10.3-103 μg/只 (30-300 nmol/只),足底注射,Capsaicin 前 15 分钟,单次剂量或 10.3-35 mg/kg (30-100 μmol/kg),口服,Capsaicin 前 60 分钟,单次剂量) 以剂量依赖方式阻断大鼠中 Capsaicin 诱导的机械性痛觉过敏。
A-425619 (3.5-35 mg/kg (10-100 μmol/kg),腹腔注射,测试前 30 分钟,单次剂量或 3.5-103 mg/kg (10-300 μmol/kg),口服,测试前 60 分钟,单次剂量) 以剂量依赖方式缓解大鼠中 CFA 诱导的慢性炎症性热痛觉过敏。
A-425619 (103 μg/只 (300 nmol/只),足底注射至炎症足,测试前 30 分钟,单次剂量) 减轻大鼠中 CFA 诱导的热痛觉过敏。
A-425619 (3.5-35 mg/kg (10-100 μmol/kg),腹腔注射,Carrageenan (MS-L60716) 后 90 分钟,单次剂量) 以剂量依赖方式缓解大鼠中 Carrageenan 诱导的急性炎症性热痛觉过敏。
A-425619 (35 mg/kg (100 μmol/kg),口服,每日两次,持续 5 天) 在大鼠中保持缓解皮肤切口诱导的机械性痛觉异常的效能。
A-425619 (35-103 mg/kg (100-300 μmol/kg),腹腔注射,测试前 30 分钟,单次) 减轻大鼠中 MIA 诱导的骨关节炎疼痛。
A-425619 (35 mg/kg (100 μmol/kg),腹腔注射,测试前 30 分钟,单次剂量) 减轻大鼠 L5/L6 脊神经结扎模型和坐骨神经结扎模型中神经病理性疼痛的机械性痛觉异常。

Animal Model: Capsaicin-induced mechanical hyperalgesia model in rats: 2 μg/10 μL of capsaicin solution was subcutaneously injected into the plantar aspect of the right hind paw of rats
Dosage: 10.3-103 μg/rats (30-300 nmol/rats)
Administration: intraplantar 15 min before Capsaicin for a single dose
Result: Showed dose-dependent blocking effects on capsaicin-induced mechanical hyperalgesia.
Showed no effect on the paw withdrawal threshold of the capsaicin-injected paw when 300 nmol/rat was injected into the contralateral paw.
Animal Model: Capsaicin-induced mechanical hyperalgesia model in rats: 2 μg/10 μL of capsaicin solution was subcutaneously injected into the plantar aspect of the right hind paw of rats
Dosage: 10.3-35 mg/kg (30-100 μmol/kg)
Administration: p.o. 60 min before Capsaicin for a single dose
Result: Showed dose-dependent preventive effects on capsaicin-induced mechanical hyperalgesia.
Achieved full efficacy at 35 mg/kg (100 μmol/kg), with an ED50 of 45 μmol/kg.
Significantly increased the paw withdrawal threshold compared with vehicle-treated rats that received Capsaicin.
Animal Model: Complete Freund’s adjuvant (CFA)-induced chronic inflammatory pain model in rats: 150 μL of 50% CFA solution was injected into the plantar surface of the right hind paw of rats
Dosage: 3.5-35 mg/kg (10-100 μmol/kg) or 3.5-103 mg/kg (10-300 μmol/kg)
Administration: i.p. 30 min before testing for a single dose or p.o. 60 min before testing for a single dose
Result: Relieved CFA-induced thermal hyperalgesia, with an ED50 of 51 μmol/kg administered intraperitoneally.
Relieved CFA-induced thermal hyperalgesia, with an ED50 of 40 μmol/kg administered orally.
Animal Model: Complete Freund’s adjuvant (CFA)-induced chronic inflammatory pain model in rats: 150 μL of 50% CFA solution was injected into the plantar surface of the right hind paw of rats
Dosage: 103 mg/rats (300 nmol/rats)
Administration: intraplantar into inflamed paw 30 min before testing for a single dose
Result: Produced a 56.2% reduction in CFA-induced thermal hyperalgesia.
Animal Model: Carrageenan-induced acute inflammatory pain model in rats: 100 μL of 1% λ-carrageenan solution was injected into the plantar surface of the right hind paw of rats
Dosage: 3.5-35 mg/kg (10-100 μmol/kg)
Administration: i.p. 90 min after Carrageenan (MS-L60716) for a single dose
Result: Relieved carrageenan-induced thermal hyperalgesia, with an ED50 of 50 μmol/kg.
Animal Model: Skin incision postoperative pain model in rats: a 1-cm longitudinal incision was made on the plantar surface (starting 0.5 cm from the proximal edge of the heel and extending toward the toes), the plantaris muscle was elevated and incised longitudinally (with origin and insertion intact), the skin was closed with two 5-0 nylon sutures
Dosage: 35 mg/kg (100 μmol/kg)
Administration: p.o. twice daily for 5 days
Result: Produced a 42.6% reduction in mechanical allodynia when tested at 24 hours after surgery (day 2), and still exerted a 37.6% analgesic effect on day 5 after surgery.
Animal Model: Monoiodoacetate (MIA)-induced osteoarthritic pain model in rats: under light halothane anesthesia, a single intra-articular injection of 3 mg MIA (dissolved in 0.05 ml sterile isotonic saline) was administered into the knee joint cavity of rats
Dosage: 35-103 mg/kg (100-300 μmol/kg)
Administration: i.p. 30 min before testing for a single dose
Result: Reduced MIA-induced increase in weight-bearing difference between the injured and non-injured hind limbs.
Animal Model: Spinal nerve (L5/L6) ligation neuropathic pain model in rats: a 1.5-cm incision was made dorsal to the lumbosacral plexus, the left L5 and L6 spinal nerves were isolated and tightly ligated with 3-0 silk threads
Dosage: 35 mg/kg (100 μmol/kg)
Administration: i.p. 30 min before testing for a single dose
Result: Reduced mechanical allodynia induced by spinal nerve injury.
性状 固体
颜色 White to off-white

化学信息

分子量 345.32
分子式 C18H14F3N3O
CAS No. 581809-67-8
别名 化合物A 425619

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (289.59 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.8959 mL14.4793 mL28.9586 mL72.3966 mL
5 mM0.5792 mL2.8959 mL5.7917 mL14.4793 mL
10 mM0.2896 mL1.4479 mL2.8959 mL7.2397 mL
15 mM0.1931 mL0.9653 mL1.9306 mL4.8264 mL
20 mM0.1448 mL0.7240 mL1.4479 mL3.6198 mL
25 mM0.1158 mL0.5792 mL1.1583 mL2.8959 mL
30 mM0.0965 mL0.4826 mL0.9653 mL2.4132 mL
40 mM0.0724 mL0.3620 mL0.7240 mL1.8099 mL
50 mM0.0579 mL0.2896 mL0.5792 mL1.4479 mL
60 mM0.0483 mL0.2413 mL0.4826 mL1.2066 mL
80 mM0.0362 mL0.1810 mL0.3620 mL0.9050 mL
100 mM0.0290 mL0.1448 mL0.2896 mL0.7240 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础